IGF1R and breast cancer: An example of the anti-IGF-IR blocking antibodies is AVE1642, which had encouraging effects in vitro and in vivo in animal models in different types of cancer including lung, hepatocellular carcinoma, PCM, Ewing sarcoma, and neuroblastoma, as well as against breast cancer metastasis [188–191].